|
|
|
|
| LEADER |
00000nam a2200000 a 4500 |
| 001 |
ELB179613 |
| 003 |
FINmELB |
| 005 |
20200520144314.0 |
| 006 |
m o d | |
| 007 |
cr cn||||||||| |
| 008 |
100507s2011 njua sb 001 0 eng d |
| 010 |
|
|
|z 2010019505
|
| 020 |
|
|
|z 9780470343425 (cloth)
|
| 020 |
|
|
|a 9780470910009 (electronic bk.)
|
| 035 |
|
|
|a (OCoLC)614271402
|
| 040 |
|
|
|a FINmELB
|c FINmELB
|d FINmELB
|
| 050 |
|
4 |
|a RC662.4
|b .M53 2011
|
| 082 |
0 |
4 |
|a 616.3/99
|2 22
|
| 245 |
0 |
0 |
|a Metabolic syndrome
|h [electronic resource] :
|b underlying mechanisms and drug therapies /
|c edited by Minghan Wang.
|
| 260 |
|
|
|a Hoboken, N.J. :
|b John Wiley & Sons,
|c c2011.
|
| 300 |
|
|
|a xiii, 494 p. :
|b ill.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Gut as an endocrine organ : the role of nutrient-sensing in energy metabolism / Minghan Wang -- Central glucose sensing and control of food intake and energy homeostasis / Lourdes Mounien and Bernard Thorens -- Abnormalities in insulin secretion in type 2 diabetes mellitus / Taly Meas and Pierre-Jean Guillausseau -- Adipokine production by adipose tissue : a novel target for treating metabolic syndrome and its sequelae / Vanessa DeClercq ... [et al.] -- Hepatic metabolic dysfunctions in type 2 diabetes : insulin resistance and impaired glucose production and lipid synthesis / Ruojing Yang -- Energy metabolism in skeletal muscle and its link to insulin resistance / Minghan Wang -- Mechanisms and complications of metabolic syndrome / Minghan Wang -- Emerging therapeutic approaches for dyslipidemia associated with high LDL and low HDL / Margrit Schwarz and Jae B. Kim -- Mechanism of action of niacin : implications for atherosclerosis and drug discovery / Devan Marar ... [et al.] -- Current anti-diabetic therapies and mechanisms / Minghan Wang -- GLP-1 biology, signaling mechanisms, physiology, and clinical studies / Remy Burcelin ... [et al.] -- Dipeptidyl peptidase IV inhibitors for treatment of diabetes / McIntosh, C.H.S. ... [et al.] -- Sodium glucose co-transporter 2 inhibitors / Margaret Ryan and Serge A. Jabbour -- Fibroblast growth factor 21 as a novel metabolic regulator / Radmila Micanovic, James D. Dunbar, and Alexei Kharitonenkov -- Sirtuins as potential drug targets for metabolic diseases / Qiang Tong -- 11-hydroxysteroid dehydrogenase type 1 as a therapeutic target for type 2 diabetes / Clarence Hale and David J. St. Jean, Jr -- Monoclonal antibodies for the treatment of type 2 diabetes : a case study with glucagon receptor blockade / Hai Yan, Wei Gu, and Murielle Veniant-Ellison -- Drug development for metabolic diseases: past, present and future / Minghan Wang.
|
| 588 |
|
|
|a Description based on metadata supplied by the publisher and other sources.
|
| 590 |
|
|
|a Electronic reproduction. Santa Fe, Arg.: elibro, 2022. Available via World Wide Web. Access may be limited to eLibro affiliated libraries.
|
| 650 |
|
0 |
|a Metabolic syndrome
|x Pathophysiology.
|
| 650 |
|
0 |
|a Metabolic syndrome
|x Chemotherapy.
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Wang, Minghan,
|d 1966-
|
| 797 |
2 |
|
|a elibro, Corp.
|
| 856 |
4 |
0 |
|u https://elibro.uam.elogim.com/ereader/bidiuam/179613
|z Texto completo
|
| 950 |
|
|
|a eLibro English
|
